Madrigal Pharmaceuticals, Inc. MDGL Business Segments — Research and Development External Expense
Discontinued — last reported Q4 '25
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept mdgl:ResearchAndDevelopmentExternalExpense.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-K, filed February 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s business segments — research and development external expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s business segments — research and development external expense?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported business segments — research and development external expense of $94.09M in Q4 2025.
- How has Madrigal Pharmaceuticals, Inc.'s business segments — research and development external expense changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s business segments — research and development external expense increased by 2165.7% year-over-year, from $4.15M to $94.09M.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s business segments — research and development external expense?
- Over 2 years (2023 to 2025), Madrigal Pharmaceuticals, Inc.'s business segments — research and development external expense has grown at a 20.9% compound annual growth rate (CAGR), from $215.53M to $315.24M.
- What does business segments — research and development external expense mean?
- The costs paid to outside partners for conducting clinical trials and research.
- How do you interpret business segments — research and development external expense?
- High spending indicates active clinical trial progression, which is necessary for future product approvals.
- How does business segments — research and development external expense compare across companies?
- Standard R&D reporting for companies outsourcing clinical development.